Mark Fineman Email

SVP, Clinical Operations and Pharmacovigilance . Glyscend

Current Roles

Employees:
11
Revenue:
$1.7M
About
Founded in 2014, Glyscend is dedicated to the development of a truly revolutionary approach to treating type 2 diabetes. The company began with the insight that bariatric surgery can lead to the immediate remission of the disease, and has since been engaged in the development of a non-invasive approach which will act on the same mechanism as surgery but fit within the current care pathway.
Glyscend Address
1812 Ashland Avenue
Baltimore, MD
United States
Glyscend Email